Recommended

Musculoskeletal Disorders In Informal Mining Wo...

Activities Offered To The Elderly In Primary He...

How Valid Are Commercially Available Medical Si...

World's Tiniest Machine

Competency Of Health Information Acquisition An...

0 votes
Toll Like Receptor 2 Signaling As A Target For Ara- Lam Mediated Protection In Man Lam Induced Pathogenesis
Author: Nivedita Majumder Lahiri, Shibali Das1, Surajit Bhattacharjee1,3, Gaurav Gupta, Suchandra Bhattacharyya Majumdar And Subrata Majumdar
Publisher: Internet Medical Publishing
12 pages
One time payment: €0.00
Required subscription: Free
Type of publication: Article
DOI: 10.3823/1018
Follow this publisher

Share this publication:

Description:

Mannosylated Lipoarabinomannan (Man-LAM) produced by virulent Mycobacteria favors mycobacterial pathogenesis by the suppression of proinflammatory microenvironment within the host cell, but Arabinosylated Lipoarabinomannan (Ara- LAM) from avirulent mycobacteria evokes proinflammatory responses via induction of Toll like receptor-2 (TLR-2) mediated signaling.

In this study, we investigated whether Ara-LAM could stimulate the TLR-2 signaling and proinflammatory cytokine gene transcription during Man-LAM induced pathogenesis in murine macrophages. Ara-LAM pretreatment (3mg/ml) of Man-LAM treated macrophages induced association of TLR-2 with its downstream factor MyD88 and subsequently of MyD88 and IRAKs, leading to Ikk phosphorylation, IkB-a degradation, finally translocation and DNA binding of NF-kB. These events culminated in the up-regu- lation of cytokines TNF-a and IL-12, nitrite generation and iNOS mRNA expression, which could be abrogated significantly by treatment of macrophages with TLR-2 specific siRNA as well as anti-TLR-2 monoclonal antibody. Based on our observations, we strongly report the TLR-2 mediated protection of Ara-LAM during Man- LAM-mediated pathogenesis.

 

About the publisher:

iMedPub Limited is a publishing house registered in UK, publishing medical books and journals since 2005. As an open service to doctors and biomedical researchers, it is driven by clinicians and researchers for themselves, while serving the interests of the general public. iMedPub disseminates research in a tiered system, beginning with our specialty books and journals and then working upwards. The grand vision of iMedPub is a world where all medical researchers and health professionals have an equal opportunity to seek, share and create knowledge. As we are a low cost academic publisher we offer the lowest article processing charges of all biomedical journals and publish books free of charges for authors.

Select a payment method